This is your last chance to buy under $20. The GALNS opportunity is way underestimated by Investors at this time. Phase III to start end of year and the product should be on the market by 2013. It's a $600 MM + opportunity. The stock will be over $30 by early next year. This company is way better managed than Genzyme. They should take over Genzyme. Not the other way around.